{"entity":{"id":"nct04616209","kind":"trial","name":"Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients","aka":[],"tldr":"A phase 1/2 trial of donor-derived NK cell infusion in non-small-cell lung cancer, run by Precision Biotech Taiwan Corp., now recruiting.","summary":"Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients is a phase 1/2 interventional study registered as NCT04616209 by Precision Biotech Taiwan Corp., with 24 participants planned, started 2020-11-15 and due to reach its primary completion in 2027-12-30. Interventions recorded: donor-derived NK cell infusion.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04616209","url":"https://clinicaltrials.gov/study/NCT04616209"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04616209","phase":"1/2","setting":"A Phase Ι & IIa, Open-label Study to Evaluate Safety and Efficacy of the Combination Therapy of Allogeneic PB103 and Standard Cancer Treatment in the IIIB/IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Patients","sponsor":"Precision Biotech Taiwan Corp.","enrolled":24,"outcomes":[]},"route":"/trials/nct04616209/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}